Lysogene Awarded Innovation Passport by the UK MHRA for the GM1 Gangliosidosis Program
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Access Pathway News
Page 16 - Access Pathway News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Access Pathway. Real-time updates on events, politics, business and more.
The UK life sciences sector: 2021 review
A look at the key developments across the sector this year - Magazine Article - PharmaTimes
United Kingdom Northern Ireland Innovative Medicines Fund Life Sciences Vision Innovative Licensing Access Pathway
Source: pharmatimes.com
MHRA News | Live Feed & Top Stories
Read the latest MHRA headlines - updated 24/7/365. We link to the best sources from around the world. Get the latest on MHRA...
Source: newsnow.co.uk
Geron Corporation: Geron Enters New Innovative Licensing and Access Pathway in the United Kingdom for Imetelstat
Innovation Passport Designation Awarded to Imetelstat for the Treatment of Lower Risk Myelodysplastic Syndromes Pathway Intended to Expedite Regulatory Review Process Geron Corporation (Nasdaq:
United States United Kingdom Sharon Mcbain Drug Administration Geron Corporation Nasdaq Access Pathway Steering Group
Source: finanznachrichten.de
EQRx and NHSE Sign Memorandum of Understanding to Enter into England's First Population Health Partnership for Cancer Drugs
Provides roadmap to commercial agreement based on shared objective to secure patient access to innovative and cost-effective cancer medicines Agreement with one of the largest public healthcare
Source: finanznachrichten.de
Innovative Licensing and Access Pathway (ILAP): New partner announcement
AWTTC joins the Innovative Licensing and Access Pathway as a permanent partner
National Institute For Health Toxicology Centre Scottish Medicines Consortium Regulatory Agency From Monday All Wales Therapeutics
Source: gov.uk
MCIT Breakthrough Devices Program Coverage Delayed
On May 14, 2021, CMS issued a new final rule that will further delay the effective date of the Medicare Coverage of Innovative Technology MCIT and Definition of Reasonable and Necessary Final Rule until no earlier than Dec. 15, 2021.
Allina Health Services Drug Administration Program Integrity Manual Biden Administration Medicare Coverage Of Innovative Technology National Coverage Determinations Ncds
Source: natlawreview.com
Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines Agency
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
United Kingdom Christopherj Schaber Us Congress Biomedical Advanced Research National Institute Of Allergy Drug Administration
Source: prnewswire.com
PCG Digital: Shining a Light on Soligenix's HyBryte Growth Opportunity
Company Connecting the Dots for Final FDA Approval New York, New York--(Newsfile Corp. - June 3, 2021) - PCG Digital -- When Soligenix (NASDAQ: SNGX) updated its NDA rollout plan, the market quickly reacted.
New York United States United Kingdom Soligenix Hybryte Christopherj Schaber Company Connecting The Dots For Final
Source: finanznachrichten.de
Soligenix, Inc.: Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition
Soligenix, Inc.: Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Japan Patent Office has allowed the patent application titled "Systems and Methods for Producing Synthetic...
United States United Kingdom Christopherj Schaber Us Congress Biomedical Advanced Research National Institute Of Allergy
Source: finanznachrichten.de